The safety profile of imatinib in CML and GIST: Long-term considerations

Archives of Toxicology

Volumn 86, Issue 1, 2012, Pages 1-12

  Thanopoulou, Eirini ^a   Judson, Ian ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

CML; GIST; Imatinib; Safety; Toxicity

Indexed keywords

ALPHA INTERFERON; CYTARABINE; DASATINIB; GLUCOSE; IMATINIB; NILOTINIB; PLACEBO;

ABNORMAL LABORATORY RESULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BLEEDING; BONE DENSITY; BONE MARROW TOXICITY; BONE METABOLISM; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; COUGHING; DERMATITIS; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EDEMA; ERYTHEMA MULTIFORME; FATIGUE; FLATULENCE; FLUID RETENTION; GASTROINTESTINAL STROMAL TUMOR; GLUCOSE METABOLISM; GRANULOCYTOPENIA; HEADACHE; HEART FAILURE; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TREATMENT DURATION;

ANIMALS; ANTINEOPLASTIC AGENTS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TIME FACTORS;

EID: 84856953592     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-011-0729-7     Document Type: Review

References (90)

1. (MetaGIST) GSTM-AG (2010) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 28(7):1247-53. doi: 10.1200/JCO.2009.24.2099
2. Agostino N, Chinchilli VM, Lynch CJ et al (2010) Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract. doi: 10.1177/1078155210378913
3. E Atallah J-B Durand H Kantarjian J Cortes 2007 Congestive heart failure is a rare event in patients receiving imatinib therapy Blood 110 17449798 1233 1237 17449798 10.1182/blood-2007-01-070144 1:CAS:528:DC%2BD2sXptFKlsrs%3D (Pubitemid 47281421)
4. M Baccarani J Cortes F Pane, et al. 2009 Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet J Clin Oncol 27 19884523 6041 6051 19884523 10.1200/JCO.2009.25.0779 1:CAS:528:DC%2BC3cXhtVWisLY%3D
5. Berman E, Nicolaides M, Maki RG et al (2006) Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 354(19):2006-13. doi: 10.1056/NEJMoa051140
6. CD Blanke GD Demetri M von Mehren, et al. 2008 Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT J Clin Oncol 26 18235121 620 625 18235121 10.1200/JCO.2007.13. 4403 1:CAS:528:DC%2BD1cXis1alsL0%3D (Pubitemid 351264357)
7. Blanke CD, Rankin C, Demetri GD et al (2008b) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26(4):626-32. doi: 10.1200/JCO.2007.13.4452 (Pubitemid 351264358)
8. M Breccia M Muscaritoli Z Aversa F Mandelli G Alimena 2004 Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment J Clin Oncol 22 15542819 4653 4655 15542819 10.1200/JCO.2004.04.217 1:STN:280:DC%2BD2crmvFyrsA%3D%3D (Pubitemid 41185138)
9. E Buchdunger J Zimmermann H Mett, et al. 1996 Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative Cancer Res 56 1 100 104 8548747 1:CAS:528:DyaK28Xit1Chsg%3D%3D
10. BR Chitteti Y-H Cheng B Poteat, et al. 2010 Impact of interactions of cellular components of the bone marrow microenvironment on hematopoietic stem and progenitor cell function Blood 115 20154218 3239 3248 20154218 10.1182/blood-2009-09-246173 1:CAS:528:DC%2BC3cXlvVags7g%3D
11. Cortes J, Kim DW, Raffoux E et al (2008) Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 22(12):2176-83. doi: 10.1038/leu.2008.221
12. JE Cortes M Baccarani F Guilhot, et al. 2010 Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study J Clin Oncol 28 20008622 424 430 20008622 10.1200/JCO.2009.25. 3724 1:CAS:528:DC%2BC3cXivFartL0%3D
13. R Dagher M Cohen G Williams, et al. 2002 Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors Clin Cancer Res 8 12374669 3034 3038 12374669 1:CAS:528:DC%2BD38XosFKiu7k%3D (Pubitemid 35155011)
14. GQ Daley RA Van Etten D Baltimore 1990 Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome Science 247 4944 824 830 2406902 10.1126/science.2406902 1:CAS:528:DyaK3cXhsFaqs7c%3D
15. M Debiec-Rychter R Sciot A Le Cesne, et al. 2006 KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours Eur J Cancer 42 16624552 1093 1103 16624552 10.1016/j.ejca.2006.01.030 1:CAS:528:DC%2BD28Xks1ertb0%3D (Pubitemid 44275331)
16. Dematteo RP, Ballman KV, Antonescu CR et al (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373(9669):1097-104. doi: 10.1016/S0140-6736(09)60500-6
17. GD Demetri M von Mehren CD Blanke, et al. 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 12181401 472 480 12181401 10.1056/NEJMoa020461 1:CAS:528:DC%2BD38XmtV2nt7s%3D (Pubitemid 34879334)
18. Dewar AL, Cambareri AC, Zannettino AC et al (2005) Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 105(8):3127-32. doi: 10.1182/blood-2004-10-3967
19. AL Dewar AN Farrugia MR Condina, et al. 2006 Imatinib as a potential antiresorptive therapy for bone disease Blood 107 16449525 4334 4337 16449525 10.1182/blood-2005-09-3568 1:CAS:528:DC%2BD28Xlt1CgsLo%3D (Pubitemid 43801358)
20. D Dingli RC Wolf A Vella 2007 Imatinib and type 2 diabetes Endocr Pract 13 17490925 126 130 17490925
21. Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031-7. doi: 10.1056/NEJM200104053441401 (Pubitemid 32267972)
22. Druker BJ, Guilhot F, O'Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408-17. doi: 10.1056/NEJMoa062867 (Pubitemid 44903745)
23. I El Hajj Dib M Gallet R Mentaverri N Sevenet M Brazier S Kamel 2006 Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity Eur J Pharmacol 551 17049513 27 33 17049513 10.1016/j.ejphar.2006.09.007 1:CAS:528:DC%2BD28XhtFKmtbbO (Pubitemid 44648069)
24. B Esmaeli VG Prieto CE Butler, et al. 2002 Severe periorbital edema secondary to STI571 (Gleevec) Cancer 95 12209733 881 887 12209733 10.1002/cncr.10729 (Pubitemid 34839681)
25. Estabragh ZR, Knight K, Watmough SJ et al (2011) A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib. Leuk Res 35(1):49-51. doi: 10.1016/j.leukres.2010.08.020
26. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM (1999) The biology of chronic myeloid leukemia. N Engl J Med 341(3):164-172. doi: 10.1056/NEJM199907153410306 (Pubitemid 29325745)
27. A Fernandez A Sanguino Z Peng, et al. 2007 An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic J Clin Invest 117 18060038 4044 4054 18060038 10.1172/JCI32373 1:CAS:528: DC%2BD2sXhsValsL3N (Pubitemid 350224113)
28. S Fitter AL Dewar P Kostakis, et al. 2008 Long-term imatinib therapy promotes bone formation in CML patients Blood 111 18042796 2538 2547 18042796 10.1182/blood-2007-07-104281 1:CAS:528:DC%2BD1cXivFakt74%3D
29. Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino AC (2010) Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? J Clin Endocrinol Metab 95(8):3763-3767. doi: 10.1210/jc.2010-0086
30. Gambacorti-Passerini CK, Kim DW, Mahon FX, Saglio G, Pane F, Guilhot F, Deininger MWN, Nagler A, Rambaldi A, Morra E, Antolini L, Kweon IY, Reiffers J, Tornaghi L, Valsecchi MG (2008) Imatinib Long Term Effects (ILTE) study: an independent, international study in CML patients In: 50th ASH Annual Meeting and Exposition. San Francisco, USA
31. S Gottschalk N Anderson C Hainz SG Eckhardt NJ Serkova 2004 Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells Clin Cancer Res 10 15475456 6661 6668 15475456 10.1158/1078-0432.CCR-04-0039 1:CAS:528:DC%2BD2cXot1Oiu7Y%3D (Pubitemid 39346563)
32. Grey A, O'Sullivan S, Reid IR, Browett P (2006) Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. N Engl J Med 355(23):2494-2495. doi: 10.1056/NEJMc062388 (Pubitemid 44903777)
33. Gronchi A, Judson I, Nishida T et al (2009) Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS). Eur J Cancer 45(19286368):1103-1106
34. G Guetens G De Boeck M Highley H Dumez AT Van Oosterom EA de Bruijn 2003 Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry J Chromatogr A 1020 14661754 27 34 14661754 10.1016/S0021-9673(03) 00775-1 1:CAS:528:DC%2BD3sXos12rt74%3D (Pubitemid 38367558)
35. Guilhot F, Druker B, Larson RA et al (2009) High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica 94(12):1669-1675. doi: 10.3324/haematol.2009. 010629
36. R Hagerkvist S Sandler D Mokhtari N Welsh 2007 Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning FASEB J 21 17135364 618 628 17135364 10.1096/fj.06-6910com (Pubitemid 46213508)
37. P Hamberg FA de Jong JG Boonstra J van Doorn J Verweij S Sleijfer 2006 Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib J Clin Oncol 24 16782905 30 31 10.1200/JCO.2006.06.5318
38. Hatfield A, Owen S, Pilot PR (2007) In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med 13(1):13; author reply 15-6. doi: 10.1038/nm0107-13a (Pubitemid 46067368)
39. MC Heinrich CL Corless GD Demetri, et al. 2003 Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol 21 14645423 4342 4349 14645423 10.1200/JCO.2003.04.190 1:CAS:528:DC%2BD2cXpsVWqu7Y%3D (Pubitemid 46621810)
40. MC Heinrich CL Corless CD Blanke, et al. 2006 Molecular correlates of imatinib resistance in gastrointestinal stromal tumors J Clin Oncol 24 16954519 4764 4774 16954519 10.1200/JCO.2006.06.2265 1:CAS:528:DC%2BD28XhtFynsrrN (Pubitemid 46630941)
41. S Hirota K Isozaki Y Moriyama, et al. 1998 Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 5350 577 580 9438854 10.1126/science.279.5350.577 1:CAS:528:DyaK1cXotVyhsw%3D%3D (Pubitemid 28067289)
42. A Hochhaus B Druker C Sawyers, et al. 2008 Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment Blood 111 17932248 1039 1043 17932248 1:CAS:528:DC%2BD1cXhvFejsLc%3D (Pubitemid 351213381)
43. Hughes TP, Branford S, White DL et al (2008) Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 112(10):3965-73. doi: 10.1182/blood-2008-06-161737
44. KA Janeway B Liegl A Harlow, et al. 2007 Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors Cancer Res 67 17909012 9084 9088 17909012 10.1158/0008-5472.CAN-07-1938 1:CAS:528:DC%2BD2sXhtFSnur7F (Pubitemid 47535893)
45. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344(14):1052-1056. doi: 10.1056/NEJM200104053441404 (Pubitemid 32267975)
46. S Jonsson B Olsson C Ohlsson M Lorentzon D Mellstrom H Wadenvik 2008 Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia Haematologica 93 18508797 1101 1103 18508797 10.3324/haematol.12373 (Pubitemid 351957034)
47. Judson IDdP E, Verweij J, Van Glabbeke M, Ma P, Peng B, Dimitrijevic S, Van Oosterom A (2003) Population pharmacokinetic (PK) analysis and PK-pharmacodynamic (PD) correlations in Phase I/II trial of imatinib in gastrointestinal stromal tumours (GIST) conducted by the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. In: ASCO Annual Meeting Chicago, vol 22. USA
48. Judson I, Ma P, Peng B et al (2005) Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 55(4):379-386. doi: 10.1007/s00280-004-0876-0 (Pubitemid 40379262)
49. H Kantarjian C Sawyers A Hochhaus, et al. 2002 Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N Engl J Med 346 11870241 645 652 11870241 10.1056/NEJMoa011573 1:CAS:528:DC%2BD38XhsFOjsr8%3D (Pubitemid 34815868)
50. HM Kantarjian F Giles N Gattermann, et al. 2007 Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Blood 110 17715389 3540 3546 17715389 10.1182/blood-2007-03-080689 1:CAS:528:DC%2BD2sXhtlarur3P (Pubitemid 350159618)
51. Kerkela R, Grazette L, Yacobi R et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12(8):908-916. doi: 10.1038/nm1446 (Pubitemid 44175142)
52. LG Kindblom HE Remotti F Aldenborg JM Meis-Kindblom 1998 Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal Am J Pathol 152 9588894 1259 1269 9588894 1:STN:280:DyaK1c3kvVejug%3D%3D (Pubitemid 28221878)
53. Komatsubara S, Mori S, Mashiba T et al (2003) Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res: Off J Am Soc Bone Miner Res 18(3):512-520. doi: 10.1359/jbmr.2003.18.3.512 (Pubitemid 36241068)
54. C Langer B Gunawan P Schuler W Huber L Fuzesi H Becker 2003 Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours Br J Surg 90 12594669 332 339 12594669 10.1002/bjs.4046 1:STN:280:DC%2BD3s%2Fot1Oitg%3D%3D (Pubitemid 36324113)
55. A Le Cesne I Ray-Coquard BN Bui, et al. 2010 Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial Lancet Oncol 11 20864406 942 949 20864406 10.1016/S1470-2045(10)70222-9 1:CAS:528: DC%2BC3cXht1ertLvF
56. B Li S Boast K de los Santos, et al. 2000 Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation Nat Genet 24 10700189 304 308 10700189 10.1038/73542 1:CAS:528:DC%2BD3cXhvFaqtL8%3D (Pubitemid 30132204)
57. F-X Mahon D Rea J Guilhot, et al. 2010 Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial Lancet Oncol 11 20965785 1029 1035 20965785 10.1016/S1470-2045(10) 70233-3 1:CAS:528:DC%2BC3cXhtlKmtrnP
58. Mauro MJ, Deininger MW (2009) Management of drug toxicities in chronic myeloid leukaemia. Best Pract Res Clin Haematol 22(3):409-429. doi: 10.1016/j.beha.2009.06.001
59. M Miettinen M Sarlomo-Rikala J Lasota 1999 Gastrointestinal stromal tumors: recent advances in understanding of their biology Hum Pathol 30 10 1213 1220 10534170 10.1016/S0046-8177(99)90040-0 1:STN:280:DC%2BD3c%2FgtFOgtQ%3D%3D (Pubitemid 29480891)
60. T Nishida K Shirao A Sawaki, et al. 2008 Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202) Int J Clin Oncol 13 18553235 244 251 18553235 10.1007/s10147-007-0746-y 1:CAS:528:DC%2BD1cXntFKhsrg%3D (Pubitemid 351871892)
61. SG O'Brien F Guilhot RA Larson, et al. 2003 Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 12637609 994 991004 12637609 10.1056/NEJMoa022457 (Pubitemid 36302244)
62. Osorio S, Noblejas AG, Duran A, Steegmann JL (2007) Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response. Am J Hematol 82(5):394-395. doi: 10.1002/ajh.20778 (Pubitemid 46651145)
63. S O'Sullivan D Naot K Callon, et al. 2007 Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms J Bone Miner Res 22 17663639 1679 1689 17663639 10.1359/jbmr.070719 (Pubitemid 351235134)
64. S O'Sullivan A Horne D Wattie, et al. 2009 Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib J Clin Endocrinol Metab 94 19174494 1131 1136 19174494 10.1210/jc.2008-2324
65. B Peng M Hayes D Resta, et al. 2004 Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients J Clin Oncol 22 14990650 935 942 14990650 10.1200/JCO.2004.03.050 1:CAS:528: DC%2BD2cXpsVKisrY%3D (Pubitemid 41103606)
66. Perik PJ, Rikhof B, de Jong FA, Verweij J, Gietema JA, van der Graaf WT (2008) Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 19(2):359-361. doi: 10.1093/annonc/mdm468 (Pubitemid 351201720)
67. RK Ramanathan MJ Egorin CHM Takimoto, et al. 2008 Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group J Clin Oncol 26 18235115 563 569 18235115 10.1200/JCO.2007.11.0304 1:CAS:528:DC%2BD1cXis1als78%3D (Pubitemid 351264349)
68. P Rousselot F Huguet D Rea, et al. 2007 Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years Blood 109 16973963 58 60 16973963 10.1182/blood-2006-03- 011239 1:CAS:528:DC%2BD2sXivVyrtL4%3D (Pubitemid 46053043)
69. BP Rubin JA Fletcher CDM Fletcher 2000 Molecular insights into the histogenesis and pathogenesis of gastrointestinal stromal tumors Int J Surg Pathol 8 11493959 5 10 11493959 10.1177/106689690000800105 1:CAS:528: DC%2BD3cXhvFaku7w%3D (Pubitemid 30129563)
70. Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340(17):1330-1340. doi: 10.1056/NEJM199904293401706 (Pubitemid 29196596)
71. CL Sawyers A Hochhaus E Feldman, et al. 2002 Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study Blood 99 11986204 3530 3539 11986204 10.1182/blood.V99.10.3530 1:CAS:528:DC%2BD38XjvVGns78%3D (Pubitemid 34534519)
72. N Scheinfeld 2006 Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate J Drugs Dermatol 5 3 228 231 16573254
73. MWM Schellings M Baumann REW van Leeuwen, et al. 2006 Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats Hypertension 47 16432052 467 474 16432052 10.1161/01.HYP.0000202487.68969.f7 1:CAS:528:DC%2BD28Xht1Cmtr8%3D (Pubitemid 43740292)
74. M Talpaz RT Silver BJ Druker, et al. 2002 Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study Blood 99 6 1928 1937 11877262 10.1182/blood.V99.6.1928 1:CAS:528:DC%2BD38XitF2nt74%3D (Pubitemid 34525471)
75. C Tarn YV Skorobogatko T Taguchi B Eisenberg M von Mehren AK Godwin 2006 Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms Cancer Res 66 16707477 5477 5486 16707477 10.1158/0008-5472.CAN-05-3906 1:CAS:528:DC%2BD28XksF2it74%3D (Pubitemid 43844976)
76. JC Trent SS Patel J Zhang, et al. 2010 Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate Cancer 116 19885836 184 192 19885836 1:CAS:528: DC%2BC3cXitFGiur4%3D
77. Van den Abbeele AD (2008) The lessons of GIST-PET and PET/CT: a new paradigm for imaging. Oncologist 13(Suppl 2):8-13. doi: 10.1634/theoncologist. 13-S2-8
78. Van Glabbeke M, Verweij J, Casali PG et al (2006) Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur J Cancer 42(14):2277-2285. doi: 10.1016/j.ejca.2006.03.029 (Pubitemid 44316904)
79. AT van Oosterom I Judson J Verweij, et al. 2001 Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study Lancet 358 11705489 1421 1423 11705489 10.1016/S0140-6736(01)06535-7 (Pubitemid 33055745)
80. K Vandyke S Fitter AL Dewar TP Hughes ACW Zannettino 2010 Dysregulation of bone remodeling by imatinib mesylate Blood 115 19890095 766 774 19890095 10.1182/blood-2009-08-237404 1:CAS:528:DC%2BC3cXhs1Giur8%3D
81. D Veneri M Franchini E Bonora 2005 Imatinib and regression of type 2 diabetes N Engl J Med 352 15758023 1049 1050 15758023 10.1056/ NEJM200503103521023 1:CAS:528:DC%2BD2MXit1WrtL4%3D (Pubitemid 40349515)
82. Verweij J, van Oosterom A, Blay JY et al (2003) Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J cancer 39(14):2006-2011 (Pubitemid 37297756)
83. Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364(9440):1127-1134. doi: 10.1016/S0140-6736(04)17098-0 (Pubitemid 39296599)
84. J Verweij PG Casali D Kotasek, et al. 2007 Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005 Eur J Cancer 43 17336514 974 978 17336514 10.1016/j.ejca.2007.01.018 1:CAS:528:DC%2BD2sXjslGnurk%3D (Pubitemid 46505099)
85. Wolf A, Couttet P, Dong M et al (2010) Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. Leuk Res 34(9):1180-1188. doi: 10.1016/j.leukres.2010.01.004
86. Wu JY, Scadden DT, Kronenberg HM (2009) Role of the osteoblast lineage in the bone marrow hematopoietic niches. J Bone Mineral Res: Off J Am Soc Bone Miner Res 24(5):759-764. doi: 10.1359/jbmr.090225
87. T Yamauchi J Kamon Y Minokoshi, et al. 2002 Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase Nat Med 8 12368907 1288 1295 12368907 10.1038/nm788 1:CAS:528: DC%2BD38XotlWlsrg%3D (Pubitemid 35373562)
88. WS Yang WJ Lee T Funahashi, et al. 2001 Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin J Clin Endocrinol Metab 86 8 3815 3819 11502817 10.1210/jc.86.8.3815 1:CAS:528:DC%2BD3MXlvFekurs%3D (Pubitemid 32755982)
89. Zalcberg JR, Verweij J, Casali PG et al (2005) Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J cancer 41(12):1751-1757. doi: 10.1016/j.ejca.2005.04.034 (Pubitemid 41132637)
90. J Zhu Y Yang L Zhou M Jiang M Hou 2010 A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome BMC Cancer 10 20465813 199 20465813 10.1186/1471-2407-10-199